As a physician-scientist and a board-certified medical oncologist, I devote my career to the improvement of kidney cancer care. My primary clinical interest is aggressive kidney cancer with a special focus on rare subtypes. I founded the MSK Translational Kidney Cancer Research Program (TKCRP) in 2011 with Robert Motzer and Paul Russo. The TKCRP aims to directly decode the molecular basis underlying disease aggressiveness and treatment response/resistance to targeted therapies. The overarching goal of our program is to develop personalized treatment regimens for the cure of metastatic kidney cancer patients.
I am a member of the American Society for Clinical Investigation, and my laboratory in the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center focuses on constructing the molecular blueprint of cancers and developing novel cancer therapeutics.